Legend Biotech Corporation (LEGN)
| Market Cap | 3.66B -39.7% |
| Revenue (ttm) | 1.27B +59.5% |
| Net Income | -91.50M |
| EPS | -0.50 |
| Shares Out | 193.77M |
| PE Ratio | n/a |
| Forward PE | 42.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,197,425 |
| Open | 18.42 |
| Previous Close | 18.63 |
| Day's Range | 18.40 - 18.97 |
| 52-Week Range | 16.24 - 37.50 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 45.62 (+141.38%) |
| Est. Earnings | Nov 11, 2026 |
About LEGN
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lym... [Read more]
Financial Performance
In 2025, Legend Biotech's revenue was $1.03 billion, an increase of 64.02% compared to the previous year's $627.30 million. Losses were -$296.80 million, 67.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for LEGN stock is "Buy." The 12-month stock price target is $45.62, which is an increase of 141.38% from the latest price.
News
Legend Biotech announces FDA clearance of LB2501 IND application
Legend Biotech (LEGN) announced that the FDA has cleared the investigational new drug, or IND, application for LB2501, an investigational in vivo CAR-T therapy designed to generate CD19/CD20 dual-targ...
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting...
Legend Biotech price target lowered to $68 from $74 at Barclays
Barclays lowered the firm’s price target on Legend Biotech (LEGN) to $68 from $74 and keeps an Overweight rating on the shares. The firm adjusted targets in the smid-cap biotechnology…
Legend Biotech price target lowered to $33 from $35 at JPMorgan
JPMorgan lowered the firm’s price target on Legend Biotech (LEGN) to $33 from $35 and keeps a Neutral rating on the shares.
Legend Biotech price target lowered to $56 from $58 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Legend Biotech (LEGN) to $56 from $58 and keeps an Outperform rating on the shares as part of a…
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend...
Legend Biotech announces five-year follow-up data from Cartitude-2 Cohort A
Legend Biotech (LEGN) announced five-year follow-up data from Cartitude-2 Cohort A evaluating Carvykti in patients with relapsed/refractory multiple myeloma after one to three prior lines of therapy a...
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therap...
Legend Biotech appoints Ingrid Zhang as CEO
Legend Biotech (LEGN) announced that its board of directors has appointed Ingrid Zhang as CEO, effective September 15. Ingrid Zhang succeeds Alan Bash, who has served as interim CEO since…
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of ...
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
Legend Biotech price target lowered to $74 from $78 at Barclays
Barclays analyst Etzer Darout lowered the firm’s price target on Legend Biotech (LEGN) to $74 from $78 and keeps an Overweight rating on the shares. The firm updated the company’s…
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and post-aut...
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executiv...
Legend Biotech price target lowered to $24 from $29 at TD Cowen
TD Cowen lowered the firm’s price target on Legend Biotech (LEGN) to $24 from $29 and keeps a Hold rating on the shares. Carvykti posted a solid Q2 with global…
Legend Biotech price target lowered to $78 from $80 at Barclays
Barclays lowered the firm’s price target on Legend Biotech (LEGN) to $78 from $80 and keeps an Overweight rating on the shares post the Q2 report. Increased uptake in the…
Legend Biotech downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform.
Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs
As previously reported, Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform with a $40 price target. Following in vivo CART readout back on June 2, Legend significantly underperfor...
Legend Biotech price target raised to $49 from $48 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Legend Biotech (LEGN) to $49 from $48 and keeps an Overweight rating on the shares.
Legend Biotech Earnings Call Transcript: Q2 2026
Achieved first quarter of company-wide profitability, driven by 50% year-over-year CARVYKTI sales growth and improved operating leverage. Strong cash position and a successful equity raise support continued pipeline advancement, with ongoing expansion into earlier lines and new markets.
Legend Biotech Earnings release: Q2 2026
Legend Biotech released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Legend Biotech Slides: Q2 2026
Legend Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Legend Biotech reports Q2 EPS 16c vs. 3c last year
Reports Q2 revenue $387.5M, consensus $351.75M. “Our second quarter results demonstrate the strength of our commercial and innovation engines at Legend Biotech (LEGN),” said Alan Bash, Interim Chief E...
Legend Biotech falls -15.1%
Legend Biotech (LEGN) is down -15.1%, or -$3.35 to $18.87.